Compare Aegon Ltd. (AEG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aegon Ltd. vs Twist Bioscience Corp — how do they compare? Aegon Ltd. trades at $8.72 (market cap $12.98B), while Twist Bioscience Corp trades at $89.51 (market cap $5.67B). The key difference: Aegon Ltd. is far larger — about 2.3× Twist Bioscience Corp's market cap, and Aegon Ltd. pays a 5.3% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| AEG | TWST | |
|---|---|---|
Market Cap | $12.98B | $5.67B |
Sector | Financials | Health |
52-Week High | $8.79 | $102.88 |
52-Week Low | $6.79 | $24.16 |
Enterprise Value | $14.11B | $5.59B |
Dividend Yield | 5.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $8.75, up 1.04% on the day, with a P/E of 12.86 and P/S of 0.55 indicating potential undervaluation. Recent earnings show mixed results, beating estimates in Q2 and Q3 2025 but missing in Q4. The company is undergoing strategic simplification, including moving its legal seat to Delaware and focusing on U.S. operations, supported by a dividend of $0.25 payable in July 2026. Technical indicators are bullish on moving averages but neutral on oscillators.
Outlook is cautiously optimistic with a 27.78% analyst buy rating, driven by restructuring benefits and U.S. market focus. Risks include execution challenges in the transition, volatile cash flows, and competitive pressures. The stock presents a value opportunity if the strategic pivot succeeds, but investors should monitor earnings consistency and debt management.
Twist Bioscience (TWST) trades at $91.03, down 8.27% in the past day, amid mixed earnings performance. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Revenue growth remains robust, rising to $377 million in 2025, but profitability challenges persist with a net income margin of -19.85%. Recent news highlights AI-driven drug discovery collaborations and insider selling activity.
The outlook is cautiously optimistic given analyst consensus favoring buys (76.93%) and a price target near current levels. Key risks include sustained cash burn, competitive pressures in synthetic biology, and execution on path to profitability. Upside hinges on revenue acceleration and margin improvement from new product launches and AI partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
